Acadia Pharmaceuticals Inc.
ACAD US0042251084
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -72% | -72% | -31% | -64% | -1% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Schneyer Mark C. EX VP |
23.65 USD |
3,498 Sold |
82,728 USD |
12/09/2025 | 15/09/2025 |
| Garofalo Elizabeth A. O |
25.98 USD |
1,600 Sold |
41,560 USD |
02/09/2025 | 02/09/2025 |
| Schneyer Mark C. EX VP |
25.18 USD |
22,000 Sold |
554,024 USD |
18/08/2025 | 18/08/2025 |
| Brege Laura O |
21.78 USD |
14,446 Sold |
314,634 USD |
04/06/2025 | 04/06/2025 |
| Kihara James CCO |
25.00 USD |
2,000 Sold |
50,000 USD |
16/05/2025 | 16/05/2025 |
| Kihara James CCO |
20.00 USD |
2,000 Sold |
40,000 USD |
16/05/2025 | 16/05/2025 |
| Kihara James CCO |
25.00 USD |
2,000 Sold |
50,000 USD |
16/05/2025 | 16/05/2025 |
| Schneyer Mark C. EX VP |
25.00 USD |
2,000 Sold |
50,000 USD |
16/05/2025 | 16/05/2025 |
| Kihara James CCO |
20.00 USD |
2,000 Sold |
40,000 USD |
16/05/2025 | 16/05/2025 |
| Kihara James CCO |
14.60 USD |
1,327 Sold |
19,374 USD |
01/05/2025 | 02/05/2025 |